Updated Apr 4, 2007 at 6:1 EST.
The
Rockville,
Maryland pharmaceutical company Rexahn is busy these days developing new medications. One of them has shown initial promising results for treating premature ejaculation ( PE ). While it is still in the initial test phase, RX-10100 was developed for depression. Yet, researchers are noting that it may provide relief for premature ejaculation ( PE ).
Animal studies demonstrate that the medication works on both serotonin and dopamine, two neurotransmitters that have been linked with premature ejaculation ( PE ) or rapid ejaculation. Mark Robbins with Catalyst Financial Resources, LLC, the company hired by Rexahn to help increase growth for the company, says, “We are excited about the premature ejaculation ( PE ) area. There is more interest in this than with Viagra and Levitra.”
Written by the PEhomepage.com Editorial Team.
Back to Articles 
Latest News Archive 
E-mail a Friend
